Engraftment of purified ALL cells in primary mice*
| Patient ID . | Cell dose . | Immune phenotype of sorted cells . | Engraftment level (%) . | Posttransplantation survival, wk . |
|---|---|---|---|---|
| L754 | 100 000 | CD20low | 63 | 24 |
| 40 | 32 | |||
| 7 | 33 | |||
| CD20high | 59 | 23 | ||
| 21 | 29 | |||
| WB51 | 62 400 | CD20low | 23 | 15 |
| 28 | 15 | |||
| 32 | 15 | |||
| 10 800 | CD20high | 37 | 16 | |
| 39 | 19 | |||
| 4000 | CD19low | 25 | 19 | |
| 28 | 20 | |||
| 31 200 | CD19high | 27 | 15 | |
| 38 | 16 | |||
| 43 | 16 | |||
| 35 | 17 | |||
| No. 1 | 100 000 | CD34highCD19low | 6 | 26 |
| 76 | 32 | |||
| No. 9 | 30 000 | CD34highCD19low | 93 | 7 |
| 99 | 16 | |||
| 200 000-250 000 | CD34highCD19high | 97 | 7 | |
| 47 | 13 | |||
| 96 | 14 | |||
| 99 | 15 | |||
| No. 12 | 10 000 | CD34highCD19high | 73 | 15 |
| CD34lowCD19high | 56 | 15 |
| Patient ID . | Cell dose . | Immune phenotype of sorted cells . | Engraftment level (%) . | Posttransplantation survival, wk . |
|---|---|---|---|---|
| L754 | 100 000 | CD20low | 63 | 24 |
| 40 | 32 | |||
| 7 | 33 | |||
| CD20high | 59 | 23 | ||
| 21 | 29 | |||
| WB51 | 62 400 | CD20low | 23 | 15 |
| 28 | 15 | |||
| 32 | 15 | |||
| 10 800 | CD20high | 37 | 16 | |
| 39 | 19 | |||
| 4000 | CD19low | 25 | 19 | |
| 28 | 20 | |||
| 31 200 | CD19high | 27 | 15 | |
| 38 | 16 | |||
| 43 | 16 | |||
| 35 | 17 | |||
| No. 1 | 100 000 | CD34highCD19low | 6 | 26 |
| 76 | 32 | |||
| No. 9 | 30 000 | CD34highCD19low | 93 | 7 |
| 99 | 16 | |||
| 200 000-250 000 | CD34highCD19high | 97 | 7 | |
| 47 | 13 | |||
| 96 | 14 | |||
| 99 | 15 | |||
| No. 12 | 10 000 | CD34highCD19high | 73 | 15 |
| CD34lowCD19high | 56 | 15 |
le Viseur et al6 and K. Wilson and K. Rehe, unpublished data, March 2009.